IL1B and COVID-19: However, it is unlikely that changes in TLR2 expression levels are exclusively responsible for differential activation of the inflammasome in S‐protein exposed cells since other TLR2 agonists (zymosan) led to secretion of IL‐1β in both COVID‐19 patient‐derived cells and cells from SARS‐CoV‐2 naïve controls.